Home > Amag Pharmaceuticals Salary

Amag Pharmaceuticals Salary

  • 14
  • 21
  • 56
Amag Pharmaceuticals average salary is $69,000, median salary is $69,000 with a salary range from $69,000 to $69,000.
Amag Pharmaceuticals salaries are collected from government agencies and companies. Each salary is associated with a real job position. Amag Pharmaceuticals salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
69,000
Average
69,000
Median
69,000
High
69,000
Total 1 Amag Pharmaceuticals Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Instructional Coordinator 69,000-69,000 Marlton, NJ, 08053 2012 Amag Pharmaceuticals Instructional Coordinator Salaries (1)
Amag Pharmaceuticals Marlton, NJ Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Amag Pharmaceuticals salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Amag Pharmaceuticals Jobs
See more Amag Pharmaceuticals Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Amag Pharmaceuticals... Information
  • AMAG Pharmaceuticals, Inc
  • Industry: BioTech/Drugs
  • City: Lexington, MA
  • Advanced Magnetics, Inc. is dedicated to the development and commercialization of therapeutic iron compounds for treating anemia as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol , the lead product in our development pipeline, has completed Phase II clinical studies for use as an iron replacement therapeutic in chronic kidney disease patients receiving erythropoietin. Ferumoxytol is also in Phase II clinical studies for use in magnetic resonance angiography, also known as MRA. In June 2000, we received an approvable letter, subject to certain conditions, from the U.S. Food and Drug Administration, the